![Characterizing the Feasibility and Performance of Real-World Tumor Progression End Points and Their Association With Overall Survival in a Large Advanced Non–Small-Cell Lung Cancer Data Set | JCO Clinical Cancer Informatics Characterizing the Feasibility and Performance of Real-World Tumor Progression End Points and Their Association With Overall Survival in a Large Advanced Non–Small-Cell Lung Cancer Data Set | JCO Clinical Cancer Informatics](https://ascopubs.org/na101/home/literatum/publisher/asco/journals/content/cci/2019/cci.2019.3/cci.19.00013/20190809/images/large/cci.19.00013t1.jpeg)
Characterizing the Feasibility and Performance of Real-World Tumor Progression End Points and Their Association With Overall Survival in a Large Advanced Non–Small-Cell Lung Cancer Data Set | JCO Clinical Cancer Informatics
![The Importance of Disease-Free Survival as a Clinical Trial Endpoint: A Qualitative Study Among Canadian Survivors of Lung Cancer | SpringerLink The Importance of Disease-Free Survival as a Clinical Trial Endpoint: A Qualitative Study Among Canadian Survivors of Lung Cancer | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs40271-021-00552-w/MediaObjects/40271_2021_552_Fig1_HTML.png)
The Importance of Disease-Free Survival as a Clinical Trial Endpoint: A Qualitative Study Among Canadian Survivors of Lung Cancer | SpringerLink
![Utility of Restricted Mean Survival Time Analysis for Heart Failure Clinical Trial Evaluation and Interpretation - ScienceDirect Utility of Restricted Mean Survival Time Analysis for Heart Failure Clinical Trial Evaluation and Interpretation - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2213177920304558-fx1ad.jpg)
Utility of Restricted Mean Survival Time Analysis for Heart Failure Clinical Trial Evaluation and Interpretation - ScienceDirect
![Cancer patient survival can be parametrized to improve trial precision and reveal time-dependent therapeutic effects | Nature Communications Cancer patient survival can be parametrized to improve trial precision and reveal time-dependent therapeutic effects | Nature Communications](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41467-022-28410-9/MediaObjects/41467_2022_28410_Fig1_HTML.png)
Cancer patient survival can be parametrized to improve trial precision and reveal time-dependent therapeutic effects | Nature Communications
![A prognostic model for overall survival of patients with early-stage non-small cell lung cancer: a multicentre, retrospective study - The Lancet Digital Health A prognostic model for overall survival of patients with early-stage non-small cell lung cancer: a multicentre, retrospective study - The Lancet Digital Health](https://www.thelancet.com/cms/asset/0fbe43e7-b69c-43d2-bff9-10ce650542f3/gr1.jpg)
A prognostic model for overall survival of patients with early-stage non-small cell lung cancer: a multicentre, retrospective study - The Lancet Digital Health
![What does OS/DFS mean? - Definition of OS/DFS - OS/DFS stands for overall survival and disease-free survival. By AcronymsAndSlang.com What does OS/DFS mean? - Definition of OS/DFS - OS/DFS stands for overall survival and disease-free survival. By AcronymsAndSlang.com](http://acronymsandslang.com/acronym_image/1107/fcf8a23a4ae2aee5ac091263d3778437.jpg)
What does OS/DFS mean? - Definition of OS/DFS - OS/DFS stands for overall survival and disease-free survival. By AcronymsAndSlang.com
![Survival curves. (A) Overall survival (median 18.2 months). (B) PS of... | Download Scientific Diagram Survival curves. (A) Overall survival (median 18.2 months). (B) PS of... | Download Scientific Diagram](https://www.researchgate.net/publication/44901947/figure/fig1/AS:601654286118955@1520456968641/Survival-curves-A-Overall-survival-median-182-months-B-PS-of-zero-versus-one-or.png)